A test case battling over funding for Alzheimer's medication was put before the court of appeal yesterday.
Drug manufacturer Eisai is campaigning for its Aricept medication to be available for patients in the earlier stages of the condition.
Last year, a high court judge ruled in favour of the National Institute for Health and Clinical Excellence (Nice) and stated that the medication should only be available to patients in the moderate stage of the disease - as at £2.50 a day it is too costly to recommend to all patients.
However, Eisai is claiming that Nice did not follow a fair and transparent process in reaching its decision.
Speaking in court yesterday, Eisai stated that some 100,000 Alzheimer's patients will be refused medication each year if this ruling is upheld.
According to the Alzheimer's Society, there are currently 700,000 people living in the UK with dementia.
Please click here for advice about how to find the right type of care.